Here, we discuss features of the mammalian immune system that enable it to orchestrate variable inflammatory responses that maintain and heal the body while protecting it from pathogenic infectious agents and tumors.
Objective. To clarify the prevalence, risk factors, outcome, and outcome-related factors of hemophagocytic lymphohistiocytosis (HLH) in patients with dermatomyositis (DM), polymyositis (PM), or clinically amyopathic dermatomyositis (CADM).
Analyzing the risk of malignancy in rheumatic diseases is a complex situation. The occurrence of cancer in patients with rheumatic disease is common, as in the general
population. At the age of 55 years, the typical age of rheumatoid arthritis (RA), about 20% of patients will be diagnosed with cancer during their remaining lifetimes.